Levicept
Levicept Ltd is a UK-based clinical-stage biotechnology company headquartered at Innovation House, Discovery Park in Sandwich, Kent, developing LEVI-04, a fully human chimeric fusion protein combining the Fc fragment of human immunoglobulin G1 with the p75 neurotrophin receptor (p75NTR) for the treatment of chronic pain. LEVI-04 is a first-in-class neurotrophin-3 (NT-3) inhibitor designed to restore neurotrophin homeostasis and deliver analgesia without the use-limiting side effects — notably rapidly progressive osteoarthritis — seen with anti-NGF antibodies. The company completed a 510+ participant Phase II study in osteoarthritis of the knee (NCT05618782) that met all primary and secondary endpoints, published the results in The Lancet in March 2026, and had its IND accepted by the US FDA in January 2026. Levicept is backed by Medicxi, Pfizer Ventures, Gilde Healthcare, Advent Life Sciences and Innovate UK. Levicept is a therapeutics developer, not a software vendor: it operates a WordPress corporate website and publishes no API, SDK, developer portal or machine-readable contract of any kind.
Levicept is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Therapeutics.
Levicept’s developer surface includes engineering blog, support, and 7 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 1
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
Other 1
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.